| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029239657 |
| P356 | DOI | 10.1038/72855 |
| P698 | PubMed publication ID | 10655067 |
| P50 | author | Erwin F. Wagner | Q40012298 |
| Koichi Matsuo | Q56810711 | ||
| P2093 | author name string | Candace Elliott | |
| Martin Tonko | |||
| Jane M. Owens | |||
| Timothy J. Chambers | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| c-Fos-induced activation of a TATA-box-containing promoter involves direct contact with TATA-box-binding protein | Q24609940 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Structure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis) | Q28506175 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line | Q29547239 | ||
| Bisphosphonates: from the laboratory to the clinic and back again | Q33697467 | ||
| Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells | Q33781682 | ||
| Conserved motifs in Fos and Jun define a new class of activation domain | Q33978710 | ||
| An inhibitor domain in c-Fos regulates activation domains containing the HOB1 motif. | Q34316542 | ||
| Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse | Q36364924 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| Direct transcriptional stimulation of the ornithine decarboxylase gene by Fos in PC12 cells but not in fibroblasts | Q36694226 | ||
| Transcriptional activation and repression by Fos are independent functions: the C terminus represses immediate-early gene expression via CArG elements | Q36720751 | ||
| Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron | Q40016658 | ||
| A novel, transformation-relevant activation domain in Fos proteins | Q40020825 | ||
| Transformation by Fos proteins requires a C-terminal transactivation domain | Q40656937 | ||
| A C-terminal domain in FosB, absent in FosB/SF and Fra-1, which is able to interact with the TATA binding protein, is required for altered cell growth. | Q40792892 | ||
| Fra-1 potentiates osteoclastic differentiation in osteoclast-macrophage precursor cell lines | Q40961317 | ||
| Osteoblasts are target cells for transformation in c-fos transgenic mice | Q41537457 | ||
| Transformation by FosB requires a trans-activation domain missing in FosB2 that can be substituted by heterologous activation domains | Q41632670 | ||
| Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization | Q46960543 | ||
| c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 | ||
| Bone and haematopoietic defects in mice lacking c-fos | Q58326969 | ||
| Pleiotropic effects of a null mutation in the c-fos proto-oncogene | Q62555352 | ||
| Yeast GCN4 as a probe for oncogenesis by AP-1 transcription factors: transcriptional activation through AP-1 sites is not sufficient for cellular transformation | Q68033260 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 184-187 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation | |
| P478 | volume | 24 |
| Q46008001 | 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. |
| Q36832193 | A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts |
| Q40367299 | A RANKL-inducible gene Znf216 in osteoclast differentiation |
| Q34551716 | A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. |
| Q34279346 | AP-1 in mouse development and tumorigenesis |
| Q43722371 | AP-1 mediated retinal photoreceptor apoptosis is independent of N-terminal phosphorylation of c-Jun |
| Q40603124 | Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity |
| Q44653546 | Activator Protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. |
| Q89820936 | Activator Protein-1 Transcriptional Activity Drives Soluble Micrograft-Mediated Cell Migration and Promotes the Matrix Remodeling Machinery |
| Q34968667 | Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells |
| Q33844646 | Baicalin positively regulates osteoclast function by activating MAPK/Mitf signalling |
| Q34366449 | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond |
| Q35145622 | Biology of the TRANCE axis |
| Q44639831 | Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin |
| Q36402724 | Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases |
| Q43624124 | Carbonic anhydrase II is an AP-1 target gene in osteoclasts |
| Q40201777 | Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition |
| Q47796415 | Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts |
| Q58326895 | Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage |
| Q42220685 | Class II and IV HDACs function as inhibitors of osteoclast differentiation |
| Q38084724 | Diabetes mellitus and inflammatory pulpal and periapical disease: a review. |
| Q36087218 | Diacylglycerol Kinase ζ (DGKζ) Is a Critical Regulator of Bone Homeostasis Via Modulation of c-Fos Levels in Osteoclasts |
| Q28201509 | Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis |
| Q40315387 | Dynamics of the metal-dependent transcription factor complex in vivo at the mouse metallothionein-I promoter |
| Q36206064 | Dysregulation of Mitochondrial Functions and Osteogenic Differentiation in Cisd2-Deficient Murine Induced Pluripotent Stem Cells |
| Q36390005 | E proteins regulate osteoclast maturation and survival |
| Q51292867 | FIAT Deletion Increases Bone Mass But Does Not Prevent High-Fat-Diet-Induced Metabolic Complications. |
| Q98205274 | FOSL1 is a novel mediator of endotoxin/lipopolysaccharide-induced pulmonary angiogenic signaling |
| Q46104653 | Fra-1 negatively regulates lipopolysaccharide-mediated inflammatory responses |
| Q40445308 | Fra-1 replaces c-Fos-dependent functions in mice |
| Q34963037 | Functions of AP1 (Fos/Jun) in bone development |
| Q92313160 | Gene Expression Profiles of Peripheral Blood Monocytes in Osteoarthritis and Analysis of Differentially Expressed Genes |
| Q58326890 | Genetic control of skeletal development |
| Q63681428 | Genetic homogeneity of the Camurati-Engelmann disease |
| Q29617421 | Genetic regulation of osteoclast development and function |
| Q51504232 | Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. |
| Q34752049 | HDAC3 and HDAC7 have opposite effects on osteoclast differentiation |
| Q34429535 | Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system |
| Q38944254 | High glucose inhibits receptor activator of nuclear factor‑κB ligand-induced osteoclast differentiation via downregulation of v‑ATPase V0 subunit d2 and dendritic cell‑specific transmembrane protein |
| Q91606550 | Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway |
| Q74268510 | How many factors are required to remodel bone? |
| Q40366542 | Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells. |
| Q33831246 | Impaired vibration of auditory ossicles in osteopetrotic mice |
| Q57675161 | Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1 |
| Q29618116 | Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts |
| Q33736852 | Interactomics profiling of the negative regulatory function of carbon monoxide on RANKL-treated RAW 264.7 cells during osteoclastogenesis |
| Q59083003 | Interfering with bone remodelling |
| Q39318199 | Interferon-β-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. |
| Q56762982 | Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1 |
| Q24673624 | Jun Dimerization Protein 2 (JDP2), a Member of the AP-1 Family of Transcription Factor, Mediates Osteoclast Differentiation Induced by RANKL |
| Q28589027 | JunB can substitute for Jun in mouse development and cell proliferation |
| Q39922891 | JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression |
| Q40838867 | JunD protects cells from p53-dependent senescence and apoptosis. |
| Q36978251 | LOXL4 is induced by transforming growth factor β1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling. |
| Q30899153 | Ligand-specific sequential regulation of transcription factors for differentiation of MCF-7 cells |
| Q36003737 | Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion |
| Q34162157 | Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation |
| Q36073894 | Mechanistic insight into osteoclast differentiation in osteoimmunology |
| Q28505493 | Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects |
| Q38074961 | Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts |
| Q33944879 | Mouse genetics have uncovered new paradigms in bone biology |
| Q46000286 | Normal and pathological bone development controlled by the AP-1 transcription factor complex. |
| Q26853017 | Nuclear receptors in bone physiology and diseases |
| Q30482448 | Osteoblasts induce Ca2+ oscillation-independent NFATc1 activation during osteoclastogenesis |
| Q39646430 | Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism |
| Q34826003 | Osteoclasts are essential for TNF-alpha-mediated joint destruction |
| Q39998421 | Osteocytes produce interferon-β as a negative regulator of osteoclastogenesis |
| Q36462661 | Osteogenic capillaries orchestrate growth plate-independent ossification of the malleus. |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q24655113 | Osteoimmunology: interactions of the bone and immune system |
| Q28580346 | Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells |
| Q34585778 | PPAR-gamma regulates osteoclastogenesis in mice |
| Q49831611 | Paeoniflorin Inhibits Receptor Activator for Nuclear Factor κB (RANK) Ligand-Induced Osteoclast Differentiation In Vitro and Particle-Induced Osteolysis In Vivo |
| Q36944827 | Phospholipase Cgamma2 mediates RANKL-stimulated lymph node organogenesis and osteoclastogenesis |
| Q89996661 | Poncirin Inhibits Osteoclast Differentiation and Bone Loss Through Down-Regulation of NFATc1 In Vitro and In Vivo |
| Q91942005 | Pregnenolone Inhibits Osteoclast Differentiation and Protects Against Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss |
| Q34282536 | Promoter specificity and biological activity of tethered AP-1 dimers |
| Q33391408 | Protective protein/cathepsin A down-regulates osteoclastogenesis by associating with and degrading NF-kappaB p50/p65. |
| Q57675150 | RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β |
| Q37286493 | RANKing c-Jun in osteoclast development |
| Q24629421 | RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro |
| Q34611297 | Reaching a genetic and molecular understanding of skeletal development |
| Q53188305 | Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. |
| Q28593319 | Regulation of osteoclast differentiation |
| Q33621757 | Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers |
| Q40220950 | Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. |
| Q40762664 | Role of TGF-beta family in osteoclastogenesis induced by RANKL. |
| Q38867124 | Role of hippocampal activity-induced transcription in memory consolidation. |
| Q36324929 | Role of nuclear factor-kappaB in the immune system and bone |
| Q55057906 | Roles of Enhancer RNAs in RANKL-induced Osteoclast Differentiation Identified by Genome-wide Cap-analysis of Gene Expression using CRISPR/Cas9. |
| Q52664272 | Root and Eruption Defects in c-Fos Mice Are Driven by Loss of Osteoclasts. |
| Q39817003 | Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts |
| Q39714931 | Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis |
| Q35577020 | Sexual Dimorphism in MAPK-Activated Protein Kinase-2 (MK2) Regulation of RANKL-Induced Osteoclastogenesis in Osteoclast Progenitor Subpopulations |
| Q34731222 | Signaling crosstalk between RANKL and interferons in osteoclast differentiation |
| Q35553533 | Signalling in osteoclasts and the role of Fos/AP1 proteins |
| Q28533497 | Sinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathways |
| Q35155505 | Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation |
| Q33299652 | Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation |
| Q58710472 | Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder |
| Q83061700 | Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis |
| Q34375122 | The AP-1 transcription factor Fra1 inhibits follicular B cell differentiation into plasma cells |
| Q92901691 | The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways |
| Q39959355 | The Fos-related antigen Fra-1 is an activator of bone matrix formation |
| Q34299184 | The Loss of Cbl-Phosphatidylinositol 3-Kinase Interaction Perturbs RANKL-mediated Signaling, Inhibiting Bone Resorption and Promoting Osteoclast Survival |
| Q37465005 | The Nuclear Receptor AhR Controls Bone Homeostasis by Regulating Osteoclast Differentiation via the RANK/c-Fos Signaling Axis. |
| Q64102143 | The RANKL-RANK Axis: A Bone to Thymus Round Trip |
| Q40720182 | The ability of Fos family members to produce phenotypic changes in epithelioid cells is not directly linked to their transactivation potentials |
| Q44800322 | The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. |
| Q33900107 | The human airway epithelial basal cell transcriptome |
| Q48226512 | The polymethoxy flavonoid sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors. |
| Q35669146 | The role of the basal stem cell of the human breast in normal development and cancer |
| Q40747418 | The utrophin gene is transcriptionally up-regulated in regenerating muscle. |
| Q34440530 | Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently |
| Q34735288 | Transcription factors in bone: developmental and pathological aspects |
| Q38290706 | Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. |
| Q40682672 | Transcriptional regulation of dentin matrix protein 1 (DMP1) by AP-1 (c-fos/c-jun) factors |
| Q36759374 | Understanding and targeting osteoclastic activity in prostate cancer bone metastases |
| Q33775139 | Up-Regulation of RANK Expression via ERK1/2 by Insulin Contributes to the Enhancement of Osteoclast Differentiation |
| Q35096808 | Using next-generation RNA sequencing to examine ischemic changes induced by cold blood cardioplegia on the human left ventricular myocardium transcriptome |
| Q64926560 | Vγ9Vδ2 T cells inhibit immature dendritic cell transdifferentiation into osteoclasts through downregulation of RANK, c‑Fos and ATP6V0D2. |
| Q39741079 | c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation |
| Q34264017 | c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs |
| Q57675135 | c-Fos suppresses systemic inflammatory response to endotoxin |
| Q42913373 | c-Fos-deficient mice are susceptible to Salmonella enterica serovar Typhimurium infection |
| Q40133925 | p73 supports cellular growth through c-Jun-dependent AP-1 transactivation |
| Q47094690 | α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways. |
Search more.